Sandoz is a global leader in generic pharmaceuticals and is part of the Novartis Group. In 2011, Sandoz had sales of $9.5 billion and reached over 400 million patients worldwide. Sandoz operates in 140 countries with around 25,000 employees and has a portfolio of over 1,100 compounds and 23,500 stock-keeping units. The document discusses Sandoz's leadership in various therapeutic areas and technologies. It also highlights Sandoz's commitment to growth in Africa through partnerships and projects aimed at improving patient care.

1. Sandoz - A Global Leader
Nick Haggar
March 2013
Head Sandoz Africa, Middle East and
Western Europe

2. Sandoz a Global Leader
This is the first dummy chapter
2 | Together Growing Faster - Sandoz and Celesio | October 10 th, 2012

3. Sandoz is a Novartis Group Company
Environment
Patient needs
Novartis portfolio
Innovative
medicines
2011 sales
USD billion
Pharmaceuticals
32.5
Eye Care
(Alcon, CIBA VISION)
10.0
Sandoz – Generics
9.5
Self-care
Consumer Health
(OTC, Animal Health)
4.6
Prevention
Vaccines and Diagnostics
2.0
Affordable
options
Full range
of healthcare
options

4. Novartis’ mission is to care for and cure patients
In 2011, Novartis treated and protected more than
1 billion patients
around the world with our products
and Sandoz medicines reached over
400 million patients

5. Sandoz is a global leader in generics
2011 generics sales1
USD million
10,196
9,473
5,559
3,320
2,432
2,358
 Present in 140 countries
 ~25,000 employees worldwide
 Portfolio of ~1,100 compounds
and >23,500 SKUs
2,313
 Rich pipeline with >800 projects
2,273
 Leader in differentiated generics
2,126
 Biosimilars pioneer
1,876
Pro forma by including all acquired companies
Note: Figures reflect sales and ROS for generics business only, including API and excluding originator (e.g. Copaxone) and proprietary business (e.g. Women’s Health)
Note: All trademarks, logos and pictures are the property of the respective owner
Source: Company annual and quarterly reports, except Actavis figures estimated based on IMS
1

6. Sandoz operates in 140 countries globally
Development*
Production*
Unterach
Holzkirchen
Barleben
Rudolstadt
Subsidiaries
Representative
offices
Boucherville
Strykow
Wilson
Kundl /
Schaftenau
Ljubljana /
Mengeš
Broomfield
Candelaria
Kaminoyama
Cambe/
Taboao
Zhongshan
Buenos Aires
Gebze
* Sample Sandoz manufacturing and development sites.
Spartan
Turbhe
Kalwe
Jakarta

7. Sandoz has an industry-leading
breadth of technologies
Biosimilars
Lyophilization
Ophthalmics
Patches/
transdermals/
thin films
Hormones
Injectables
Inhalers
Cytotoxics
API
Innovative
solid
formulations
Implants
Dermatology

8. Anti-Infectives: Sandoz is the leading Gx player
Total anti-infectives sales
USD bn (FY 2011)
Pfizer
3.7
CAGR1
Percent (200911)
-6%
GlaxoSmithKline
1.7
-4%
Sandoz
1.7
+4%
Sanofi 2
1.3
-5%
Teva
1.3
-8%
Merck & Co.
1.2
-12%
Johnson & Johnson
1.0
-25%
Daiichi Sankyo 2
0.9
-5%
Medicis
0.8
+22%
Bayer
0.7
-2%
1
2
Growth rate at constant currency rate
Incl. Generic business
Source: IMS, global market, anti-infectives defined as J1 (antibacterials)
Gx
Originator

9. Sandoz in first dummy chapter
This is the Africa

10. Commitment and Growth in Africa
World Economic Forum, Addis Ababa
Wide range of bilateral meetings
•4 Ministers
•7 NGOs (Bill & Melinda Gates
Foundation, Director-General of
Red Cross, ...)
•Private companies (Philips, Coca
Cola, Merck, ...)
•Development organizations (GIZ,
US African Development
Foundation, ...)
Minister of Industry and Trade, Egypt
Minister of Health,
Ethiopia
AU-UNIDO Conference on Diversified Economy and Manufacturing, Addis
Ababa of bilateral meetings
Wide range
•Local manufacturers from Ethiopia, Kenya,
Botswana, Sierra Leone, ...
•UN, WHO, GIZ, British Embassy, German
Embassy, Swiss Embassy

11. 5 joint projects to improve patient’s life Zambia Example
Health shops
Cardiovascular Academy
Build high quality,
affordable portfolio
Rheumatic Heart
Disease
Zambora Project

12. Focus Areas
Quality
Regulatory
Distribution
Affordability
Partnerships

13. REGIONAL FOCUS: GROWTH
OPPORTUNITIES FOR PHARMA COMPANIES
IN THE WEST AFRICAN MARKET
DR YAW ADU GYAMFI, CEO, DANADAMS PHARMACEUTICAL
INDUSTRIES
NICK HAGGAR, HEAD, WESTERN EUROPE, MIDDLE EAST &
AFRICA,
SANDOZ
MODERATOR: DR VINCE S. THOMAS, MANAGING DIRECTOR, V.S
THOMAS GLOBAL HEALTH STRATEGY CONSULTING